Sydney, Australia (ABN Newswire) – VGI Health and fitness Technology Minimal (NSX:VTL) is delighted to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced recruitment of clients for its Section II medical review in Non-Alcoholic Fatty Liver Ailment (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).
The research will enrol eighty sufferers throughout eight web-sites in Australia, with two web sites The Gallipoli Clinical Research Basis (GMRF) in Queensland and The Royal Melbourne Healthcare facility in Victoria now commencing recruitment of patients.
This research will be a randomised, double-blind, placebo-controlled Stage II scientific study on NAFLD/NASH to analyse the efficacy and protection of IVB001, a drug candidate based mostly on the noninvasive and immediate delivery of tocotrienols utilizing Invictus’ patented transmucosal supply system.
Professor Darrell Crawford, the Director of Investigation for the GMRF, a Member of the Invictus Scientific Advisory Board and the Affiliate Dean, Strategic Development for the School of Drugs for the University of Queensland, mentioned “NAFLD/NASH is a tough and intractable condition to handle and there are now no treatments accepted by significant regulatory bodies this sort of as the Therapeutic Items Administration listed here in Australia or the Food and Drug Administration in the US.
Invictus’ NAFLD/NASH drug candidate, IVB001, has the possible to tackle various features of this demanding disease which include the steatosis (collecting of excess fat in liver cells), the inflammation triggered by the steatosis and the fibrosis (scarring brought about by collagen) resulting from the irritation.”
“There is solid proof from scientific research executed by other teams on orally-sent tocotrienols which clearly show promising signals of efficacy against NAFLD/NASH and we are of the look at that Invictus’ transmucosal delivery platform would boost this efficacy” commented Dr David Kingston, Invictus’ Chief Scientific Officer and Chair of the Scientific Advisory Board.
Additional review websites are anticipated to begin recruitment of individuals shortly and Invictus is advancing preparations for a Stage II scientific analyze in Pancreatic Adenocarcimoma (pancreatic most cancers) which is anticipated to commence recruitment of patients later this yr.
About VGI Wellbeing Engineering Minimal:
VGI Wellness Technological innovation Limited (NSX:VTL) is an Australian public shown biotechnology firm acquiring and commercialising novel nutritional dietary supplements and prescription medications dependent on organic items (tocotrienols) which have broad therapeutic possible, together with: Delayed Onset Muscle Soreness, muscle mass restoration, workout stamina, Non-Alcoholic Fatty Liver Illness (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic most cancers, hyperlipidaemia, hypertension and diabetic issues. VTL owns and controls patent and other intellectual assets rights for novel methods to non-invasively delivering tocotrienols immediately to the focus on tissues. The Company has a merchandise advancement plan for evidence-based mostly nutraceuticals and a medical growth program for prescription medicines.
VGI Wellbeing Technologies Constrained
Make contact with:
Glenn Tong CEO and Taking care of Director Ph: +61 () 412 193 350 Andrew Crook Trader and Media Relations Ph:+61 () 419 788 431 Catriona Glover Enterprise Secretary Tel: +61 () 402 328 200